Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/60—Sugars; Derivatives thereof
  • A61K8/602—Glycosides, e.g. rutin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q7/00—Preparations for affecting hair growth
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
  • A61Q1/14—Preparations for removing make-up

Definitions

• lactose-derived C-glycosides as a protector and / or activator of ⁇ T lymphocytes
• the present invention relates to the use of at least one lactose-derived C-glycoside of the general formula (I)
• ⁇ T cells gamma-delta T cell lymphocyte cells
• the composition will find applications to promote the tissue repair of the skin, to rebalance epidermal proliferation and differentiation disorders that appear with lack of sleep, to improve the appearance of the hair and limit hair loss.
• Human skin consists of a superficial compartment, the epidermis and a deep compartment, the dermis.
• the epidermis is composed mainly of three types of cells which are keratinocytes (majority), melanocytes and Langerhans cells. Each of these cell types contributes, by its own functions, to the essential role played in the body by the skin, in particular the protective role of the body against external aggressions.
• the dermis provides the epidermis with a solid support. It is also its nurturing element. It consists mainly of fibroblasts and an extracellular matrix composed mainly of collagen, elastin and a fundamental substance. There are also leucocytes, mast cells and tissue macrophages. Finally, the dermis is crossed by blood vessels and nerve fibers.
• the skin constitutes a barrier against external aggressions, in particular chemical, mechanical, and as such a number of reactions of defense against the environment (climate, ultraviolet rays, tobacco, pollution ...) and / or xenobiotics (as for example some drugs) occur at its level.
• external aggressions in particular chemical, mechanical, and as such a number of reactions of defense against the environment (climate, ultraviolet rays, tobacco, pollution ...) and / or xenobiotics (as for example some drugs) occur at its level.
• xenobiotics as for example some drugs
• Human lymphocytes are characterized by a receptor for a specific antigen (TCR, T cell receptor). 95% of the lymphocyte population consists of lymphocytes whose T-cell antigen receptors are transmembrane hetero-dimers composed of an alpha and beta ( ⁇ T) chain. Only about 5% of lymphocytes express gamma and delta chains ( ⁇ T), this population has been demonstrated by Tonegawa et al. in 1984.
• TCR T cell receptor
• ⁇ T lymphocytes are mainly located in the blood (for the V ⁇ 2 subtype) and in the epithelia: epidermis and mucosa (for the resident V ⁇ 1 subtype). They express the CD3 receptors and the TCR gamma-delta receptors (respectively with two variable regions according to their circulating localization: V ⁇ 9V ⁇ 2 or resident: V ⁇ 9V ⁇ 1) and are often CD4 (-) - CD8 (-), their activation is not restricted to the major histocompatibility complex (MHC) and is attributed a role of cellular homeostasis.
• MHC major histocompatibility complex
• the gamma chain is encoded by chromosome 7 and the delta chain by the 14th.
• ⁇ T lymphocytes constitute a T lymphocyte population whose analysis of the structural characteristics has modified the knowledge on the interactions between the T cell and its antigen. The importance of the immunoregulatory functions exerted by these cells opens new perspectives in the understanding of the mechanisms that contribute to the maintenance of the homeostasis of the immune system. ⁇ T lymphocytes seem to intervene very early in the regulation of innate immunity.
• IGFs Insulin Growth Factors
• GH Growth hormone
• GH acts on the peripheral organs and the brain either directly or indirectly by stimulating the synthesis of growth factors, such as insulin-like growth factors (IGF I and II) or epidermal growth factor (EGF) or that of their receptors.
• IGF I and II insulin-like growth factors
• EGF epidermal growth factor
• the direct action of GH is of the anti-insulin type by promoting lipolysis in the adipose tissue.
• I 1 IGF-I GH stimulates the incorporation of amino acids in proteins, the growth of cartilage and bone (linear growth) and cell proliferation of many organs, including the skin.
• Growth hormone and other somatotropic hormones are able to maintain its youthful appearance in the body. They intervene, indeed, in the management of its metabolism, determining not only the final size of the adult body but giving again, volume, tone and firmness to the organs and tissues, particularly to the muscles.
• growth hormone is involved in everything that provides a good self-image and a positive mind. It strengthens the body and makes the back straighter, developing the muscles of the shoulders and pelvis. It also decreases fat, especially in the belly, increases libido and sexual energy, regrowth and hair coloring, as well as elasticity of the skin. In a way that may be less apparent but equally beneficial, its effects can be seen in better resistance to effort, less prolonged sleep and more profitable, balanced blood pressure, better visual, auditory and cerebral acuity.
• GH is pulsatile secretion and this character is a determining factor for a large number of biological effects of the hormone.
• NGF1 insulin like growth factor 1
• IGFI insulin like growth factor 1
• IGF1 and IGF2. Two types are classically described: IGF1 and IGF2. These are two peptides whose amino acid sequence is similar to that of insulin, hence their name.
• the NGF1 receptor has a shared affinity with insulin. This is not the case for the NGF2 receiver. With aging, the rate of IGFs decreases to stabilize in adulthood: it is somatopause (D. Radman "Effects of human growth hormone in men over 60 years old", N. Engl J. Med 1990, July 323 (1): 1-6).
• IGFI IGFI alone stimulates the proliferation of keratinocytes (Neely EK - Insulin-like growth factors are mitogenic for human keratinocytes and squamous cell carcimona - J Invest Dermatol 1991 Jan; 96 (1) : 104-10). With regard to fibroblasts, it is also known that IGFI stimulates the synthesis of GAGs, and the synthesis of collagen. In addition, studies have shown a significant participation of IGFs in healing. Finally, a study conducted in vivo in humans has shown that a percutaneous treatment with IGF1 for one month resulted in an increase in skin thickness.
• This control of the release of IGFI contributes to the maintenance of epidermal homeostasis which regulates, in particular, the balance between proliferation and differentiation of epidermal cells.
• the present invention relates to the use of at least one compound of general formula (I):
• R represents a linear or branched, saturated or unsaturated alkyl, perfluoroalkyl, hydrofluoroalkyl chain, a cycloalkyl, cycloperfluoroalkyl or cyclohydrofluoroalkyl ring, comprising from 1 to 18 carbon atoms, a phenyl radical, said chain, said ring or said radical possibly being interrupted; by one or more heteroatoms selected from oxygen, sulfur, nitrogen, silicon, and optionally substituted by at least one radical selected from -OR'i, -SR "i, -NR"' ⁇ , -COOR " 2 , -CONHR '' 2 , -CN, halogen, perfluoroalkyl, hydrofluoroalkyl and / or at least one optionally substituted cyclo
• R ' 2 , R'" 2 which may be identical or different, represent a hydrogen atom, a radical chosen from a linear or branched, saturated or unsaturated alkyl, hydroxyl, perfluoroalkyl and / or hydrofluoroalkyl radical comprising from 1 to 20 atoms of carbon ;
• R'i, R "i, R" 2 , R "" i identical or different, represent a hydrogen atom, a radical chosen from a linear or branched, saturated or unsaturated alkyl, perfluoroalkyl and / or hydrofluoroalkyl radical, comprising from 1 to 20 carbon atoms, with the following restrictions: - R1 and R2 can not be simultaneously a hydroxyl radical;
• R'2 and R''1 can not be simultaneously a hydroxyl radical, to maintain and / or restore the balance between proliferation and differentiation of epidermal cells.
• R represents an alkyl chain, linear or branched, saturated or unsaturated, a cycloalkyl ring, comprising from 1 to 10 carbon atoms, a phenyl radical, said chain, said ring or said radical possibly being substituted by at least one radical chosen from -OR 1 ! , -NR 1 ",", -COOR “ 2 , -CONHR”" 2 ;
• R ' 2 , R'" 2 which may be identical or different, represent a hydrogen atom, a radical chosen from an alkyl radical, hydroxyl radical, linear or branched, saturated or unsaturated, comprising from 1 to 8 carbon atoms;
• R'i, R "i, R" 2, R “'i, identical or different represent a hydrogen atom, a radical chosen from a linear or branched, saturated or unsaturated alkyl radical containing from 1 to 8 atoms of carbon.
• X represents a group chosen from: -CO-, -CH (NR 1 R 2 ) -, -CHR '; R represents a linear or branched, saturated or unsaturated alkyl chain, a cycloalkyl ring comprising from 1 to 10 carbon atoms, and a phenyl radical.
• C-glycoside compounds which can be used according to the invention represent a sub-family of the C-glycoside derivatives described in EP 1 345 919, they can be prepared according to the process described in this document.
• a protector and / or stimulator of ⁇ T lymphocytes of the skin and / or mucous membranes leads to the increased release of IGFI by epidermal cells and promotes the physiological proliferation of keratinocytes and / or decreases epidermal differentiation.
• the present invention also relates to the cosmetic use of at least one compound of general formula (I) for mimicking the effect of sleep on renewal epidermal cell or to either supplement the effect of sleep on the skin during a normal rest or, to supplement the dysfunction of skin epidermal functions that may occur during a lack of sleep.
• the use according to the invention will thus more specifically aim to mimic the effects of sleep on epidermal cellular renewal to prevent and / or correct the cutaneous effects characteristic of lack of sleep and / or to stimulate the skin during the absence of sleep and induce the renewal of epidermal cells.
• the use according to the invention makes it possible to prevent and / or treat the cutaneous manifestations generated by the slowing down of the renewal of the cells, thus leads to the cellular regeneration of the epidermis and improves the appearance of the surface of the skin.
• the consequences of this activity is that the use of at least one compound of general formula (I) according to the invention on a subject in need of sleep makes it possible more particularly to treat drawn and / or dug features, to standardize the complexion.
• the present invention relates to a cosmetic treatment method for erasing the cutaneous signs of fatigue by stimulating the regeneration of epidermal cells, characterized in that it comprises the application to the face of at least one compound of general formula (I).
• At least one compound of general formula (I) also makes it possible to prevent and / or treat hair disorders such as a change in the density, the quantity or the quality of the hair, as a consequence, for example, of slowing down, stopping growth or falling hair follicles.
• the present invention relates to the use of at least one compound of general formula (I) for preventing the thinning of the keratinous fiber and / or inducing the growth of hair and / or hair to induce regrowth of hair or denser hair. Also, the invention also relates to the use of at least one compound of general formula (I) as an agent for inducing and / or stimulating the growth of keratin fibers, human hair or hairs, in particular human and / or braking their fall and / or increase their density.
• the keratinous fibers By increasing the density of the keratinous fibers, and in particular the capillary density, it is intended to increase the number of keratin fibers, in particular the hair, per cm 2 of skin such as the scalp.
• hair treatment compositions for limiting and / or preventing hair loss and thus treating alopecia of any nature whatsoever and / or promote the growth of healthy hair.
• the cosmetic use according to the invention of at least one compound of general formula (I) can be carried out using a cosmetic composition for the care and / or makeup of keratinous fibers.
• the invention also applies to keratinous fibers of mammals of the animal species (dog, horse or cat for example).
• the human keratinous fibers to which the invention applies are in particular the hair, the eyebrows, the eyelashes, the beard and mustache hairs. More specifically, the invention is applicable to human hair and / or eyelashes.
• the subject of the present invention is also a process for the cosmetic treatment of human keratinous fibers and / or the skin from which said fibers, including the scalp, emerge, intended in particular to stimulate the growth of human keratinous fibers such as the hair and the cilia of being human and / or curbing their fall, characterized in that it consists in applying to the human keratin fibers and / or the skin from which said fibers emerge, a cosmetic composition comprising an effective amount of at least one compound of general formula (I), to leave it in contact with the keratinous fibers and / or the skin from which said fibers emerge, and possibly to rinse the keratinous fibers and / or said skin.
• a cosmetic composition comprising an effective amount of at least one compound of general formula (I), to leave it in contact with the keratinous fibers and / or the skin from which said fibers emerge, and possibly to rinse the keratinous fibers and / or said skin.
• This treatment method has the characteristics of a cosmetic process insofar as it makes it possible to improve the esthetics of the keratinous fibers and in particular the hair and the eyelashes by giving them a greater vigor and an improved appearance. In addition, it can be used daily for several months, without a medical prescription. More specifically, the subject of the present invention is a process for the cosmetic care of human hair and / or scalp, with a view to improving their state and / or their appearance, characterized in that it consists in applying to the hair and or or the scalp, a cosmetic composition comprising a compound of general formula (I), to leave it in contact with the hair and / or the scalp, and possibly to rinse the hair and / or the scalp.
• a cosmetic composition comprising a compound of general formula (I), to leave it in contact with the hair and / or the scalp, and possibly to rinse the hair and / or the scalp.
• the subject of the invention is also a process for the cosmetic care and / or makeup of these human eyelashes, with a view to improving their state and / or their appearance, characterized in that it consists in applying a composition of mascara comprising at least a compound of general formula (I) and to leave it in contact with the eyelashes.
• This mascara composition can be applied alone or as an undercoat of a conventional pigmented mascara and removed as a conventional pigmented mascara.
• compositions used according to the invention can be administered orally, enterally or else topically, preferable topical administration.
• compositions may be in any suitable form such as an oral solution, capsules, dragee, soft or hard capsule, tablets to swallow or chewable, granules to dissolve, syrup, solid or liquid food ...
• the composition may also be in the galenical forms conventionally used for topical application and especially in the form of lotion or serum-type dispersions, of liquid or semi-liquid consistency emulsions of the milk type, obtained by dispersion of a fatty phase. in an aqueous phase (O / W) or conversely (W / O), or suspensions or emulsions of soft, semi-solid or solid consistency of the cream or gel type, or multiple emulsions (W / O / W or H / E / H), microemulsions, nanoemulsions, vesicular dispersions of ionic and / or nonionic type, or wax / aqueous phase dispersions.
• These compositions are prepared according to the usual methods.
• transdermal system allowing active or passive release of the active (s) by transdermy, for example patch or gel patch (hydrogel).
• the composition used according to the invention can thus constitute a composition for treating or caring for the skin (including the scalp), keratin fibers (hair, eyelashes, eyebrows), nails or lips, or a sunscreen or artificial tanning composition, or a cleansing or make-up remover of the skin, hair, eyebrows or eyelashes, a deodorant product or a perfume compound. It is then generally not colored or weakly colored, and it may optionally contain cosmetic or dermatological active ingredients. It can then be used as a skin or lip care base (lip balms, protecting the lips from cold and / or sun and / or wind) as a day or night care cream for the skin of the skin. face and / or body. It may, in addition, be in the form of shampoo treatment or not, dye or not, and conditioner.
• the composition used according to the invention may also constitute a colored cosmetic composition and in particular a makeup composition for the skin, keratinous fibers (hair or eyelashes) and / or mucous membranes, in particular a foundation, a blush, a makeup with cheeks or eyes, a concealer compound in a stick, a lipstick or a lip gloss, optionally having care or treatment properties.
• a colored cosmetic composition (beige or green) intended to correct the color of the complexion.
• composition used according to the invention may also comprise active agents which will be chosen by those skilled in the art so that they do not adversely affect the effect of the compounds of general formula (I).
• compositions will be for cosmetic use and in particular for topical application to the skin and keratinous fibers, and more especially to the scalp, the hair and eyelashes, they can be in any known galenic forms adapted to the mode of use, for example, those mentioned above.
• the composition for application to the scalp or the hair may be in the form of a hair care lotion, for example a daily or biweekly application, a shampoo or a hair conditioner, in particular Particular application bi-weekly or weekly, a liquid soap or solid daily scalp cleansing, a product shaping the hairstyle (lacquer, product for setting, styling gel) , a masking mask, a cream or a foaming gel for cleaning the hair. It can still be in the form of hair dye or mascara to be applied by brush or comb.
• the composition to which the invention applies may be in the form of a mascara, pigmented or not, to be applied to the brush on the eyelashes or on the hairs beard or mustache.
• composition according to the invention is in the form of hair cream or lotion, shampoo or hair conditioner, hair mascara or eyelash.
• the compound of general formula (I) it is possible to associate with the compound of general formula (I) at least one additional capillary active compound promoting the regrowth and / or limiting the fall of keratinous fibers and in particular the hair.
• Said hair active may be chosen from: anti-seborrhoeic such as certain sulfur amino acids, 13-cis retinoic acid, cyproterone acetate;
• agents for controlling squamous conditions of the scalp such as zinc pyrithione, selenium disulphide, climbazole, undecylenic acid, ketoconazole, piroctone olamine (octopirox) or ciclopirocton (ciclopirox); the active agents stimulating the regrowth and / or promoting the slowing down of the hair loss, it may more particularly be mentioned without limitation:
• Nicotinic acid esters especially including tocopheryl nicotinate, benzyl nicotinate and alkyl nicotinates C-
• -Cg such as methyl or hexyl nicotinates
• Pyrimidine derivatives such as 2,4-diamino-6-piperidinopyrimidine 3-oxide or "Minoxidil” described in the patents US 4,139,619 and US 4,596,812; Aminexil or 2,4 diamino pyrimidine 3 oxide described in WO96 / 09048;
• antibiotic agents such as macrolides, pyranosides and tetracyclines, and in particular Erythromycin;
• Cinnarizine, Nimodipine and Nifedipine Cinnarizine, Nimodipine and Nifedipine
• hormones such as estriol or analogues, or thyroxine and its salts
• antiandrogenic agents such as oxendolone, spironolactone, diethylstilbestrol and flutamide
• - cromakalim and nicorandil such as estriol or analogues, or thyroxine and its salts
• composition according to the invention can be applied to the alopecic areas of the scalp and hair of an individual, and possibly left in contact for several hours and possibly rinsed.
• ⁇ T lymphocytes The activity on the proliferation of ⁇ T lymphocytes is tested as follows: human peripheral blood cells are cultured in the presence of an RPMI culture medium supplemented with L-Glutamine (2 mM), penicillin / streptomycin (50 ⁇ g / 50Ui / ml), and fetal calf serum (10%).
• the C-glycoside derivatives are added at different concentrations (10 to 0.05mM) as well as phytohemagglutin (PHA at 5 * G / ml), a positive control of lymphocyte proliferation. After 3 days of culture the proliferation is revealed by BrdU labeling.
• the tested derivative has a high capacity for proliferation of human lymphocytes at concentrations greater than 1 mM.
• Compound 3 1, 00 Strontium chloride 5.00 Antioxidant 0.05 Isopropanol 40.00 Preservative 0.30 Water qs 100%.
• This mascara is applied on the eyelashes like a classic mascara with a mascara brush.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Dermatology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Birds (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Cosmetics (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=37311842

Family Applications (1)

Country Status (5)

Families Citing this family (1)

Family Cites Families (4)

• 2006
  • 2006-04-07 FR FR0651271A patent/FR2899477B1/fr not_active Expired - Fee Related
• 2007
  • 2007-04-05 CN CNA2007800212376A patent/CN101466351A/zh active Pending
  • 2007-04-05 EP EP07727854A patent/EP2012743A1/de not_active Withdrawn
  • 2007-04-05 US US12/296,311 patent/US20100160251A1/en not_active Abandoned
  • 2007-04-05 WO PCT/EP2007/053386 patent/WO2007116023A1/fr active Application Filing

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events